Testing for MLH1 mutations and hypermethylation is crucial for the diagnosis and management of Lynch syndrome and other related cancers. Techniques such as immunohistochemistry (IHC) and polymerase chain reaction (PCR) are commonly used. IHC can detect the absence of MLH1 protein expression, while PCR can identify MSI and specific gene mutations.
